In CRC, RUNX3 is taken as a tumor suppressor since its methylation is a significant risk factor for tumor development and high nuclear expression of RUNX3 is associated with better survival (Weisenberger et al., 2006; Soong et al., 2009). This evidence concerns the gene RUNX3 and colorectal carcinoma.